옵션 체인은 다양한 행사가격과 만기일에 대한 MiMedx Group의 주식 옵션 주요 데이터를 보여줍니다. 트레이더들은 이 정보를 사용하여 잠재적 거래를 분석하고 MiMedx Group에 대한 시장 심리를 평가합니다..

MiMedx Group (NASDAQ:MDXG) 주식, 옵션 체인

MiMedx Group

MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are primarily targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, it sells allografts for ophthalmic surgery and dental applications through licenses to third parties.

MIMEDX GROUP INC

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

ALVO

BBGI

BCAX

ELTX

FOXO

ISPC

JBHT

LYTS

MDXG

NATR

NUKK

OFIX

TMCI

TXNM

VIAV

WILC

버서스 시스템즈(NASDAQ:VS)의 주가는 회사가 국제적인 입지를 성장시키기 위한 전략의 일환으로 회사가 브라질 시장으로의 확장을 발표한 후 급등했다. 버서스 시스템즈의 주가가 금요일 프리마켓 거래에서 71.2% 상승하여 $3.39에 거래되었다.

버서스 시스템즈 주식이 약 71% 상승한 이유: 프리마켓에서 움직이는 20개의 주식

MiMedx Group Inc

MiMedx Group ( ($MDXG) ) has provided an announcement. MiMedx Group reported a 3% increase in net sales for Q3 2024, reaching $84 million, driven b...

MiMedx Group Reports 3% Sales Increase in Q3 2024

MiMedx Group, Inc. (MDXG) Q3 2024 Earnings Call Transcript

MiMedx Group Inc. ( ($MDXG) ) has realeased its Q3 earnings. Here is a breakdown of the information MiMedx Group Inc. presented to its investors. M...

MiMedx Group Inc. Reports Q3 2024 Financial Results

MiMedx (MDXG) provided the following update on the Local Coverage Determinations, LCDs, regarding "Skin Substitute Grafts/Cellular and Tissue-Based...

MiMedx provided update on LCDs regarding skin substitute

Get caught up quickly on the top news and calls moving stocks with these five Top Five lists. 1. STOCK NEWS: Disney (DIS) reported better-than-expe...

Disney reports Q4 beat, Capri-Tapestry call off deal: Morning Buzz

Craig-Hallum analyst Chase Knickerbocker maintained a Buy rating on MiMedx Group (MDXG – Research Report) today. The company's shares closed yester...

Craig-Hallum Reaffirms Their Buy Rating on MiMedx Group (MDXG)

In a report released today, Carl Byrnes from Northland Securities reiterated a Buy rating on MiMedx Group (MDXG – Research Report), with a price ta...

Northland Securities Sticks to Their Buy Rating for MiMedx Group (MDXG)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Bristol-Myers Squibb (BMY – Research Report) and M...

Analysts Offer Insights on Healthcare Companies: Bristol-Myers Squibb (BMY) and MiMedx Group (MDXG)

Northland Securities analyst Carl Byrnes maintained a Buy rating on MiMedx Group (MDXG – Research Report) today and set a price target of $12.00. T...

Northland Securities Sticks to Its Buy Rating for MiMedx Group (MDXG)

MiMedx (MDXG) Group announced that it has filed a lawsuit against Surgenex in the United States District Court for the District of Arizona. The com...

MiMedx files patent infringement lawsuit against Surgenex

AAPL

AMZN

BILI

BLNK

CBRL

CPRI

CRKN

CSCO

GAMB

HIMS

HNHAF

HNHPF

NVDA

OMER

PLUG

PZZA

SFTBF

SFTBY

SPOT

Press Releases

THIRD DEFENDANT FIGHTS BACK AGAINST MiMEDX, CLAIMING 'DISREPUTABLE AND UNLAWFUL BUSINESS PRACTICES'

EX-MiMEDX EMPLOYEES ALLEGE  MiMEDX "PRESSURE[D] HEALTHCARE PROVIDERS TO TREAT WOUNDED VETERANS, DIABETICS, CHRONIC WOUND SUFFERERS, AND OTHER PATIENTS WITH MEDICALLY UNNECESSARY OR UNSUITABLE PRODUCTS"

MIMEDX Showcases Leading Allograft Portfolio and Its Latest Scientific and Clinical Evidence at SAWC Fall

Health Care

General

MIMEDX Points to The New York Times Article on the Vast Benefits of Placental Tissue

MIMEDX to Host Third Quarter 2024 Operating and Financial Results Conference Call on October 30

Earnings

MIMEDX Announces Third Quarter 2024 Operating and Financial Results

MIMEDX to Participate in Upcoming Investor Conferences

MIMEDX's Advocacy to Rein in Runaway Medicare Spend for Skin Substitutes Has Yielded Significant Results with Planned Implementation of LCDs

Legal

MIMEDX Files Patent Infringement Lawsuit Against Surgenex

Ardelyx

Arcutis Biotherapeutics, Inc. - Common stock

Arcutis Biotherapeutics

BioCryst Pharmaceuticals, Inc. - Common Stock

BioCryst Pharma

CareDx

Celldex Therapeutics, Inc. - Common Stock

Celldex Therapeutics

Day One Biopharmaceuticals, Inc. - Common Stock

Day One Biopharmaceutical

Dyne Therapeutics

Galapagos NV - American Depositary Shares

Galapagos

Immunocore Holdings plc - American Depositary Shares

Immunocore Hldgs

Kiniksa Pharmaceuticals, Ltd. - Class A Ordinary Shares

Kiniksa Pharmaceuticals

Myriad Genetics

Nurix Therapeutics

Intellia Therapeutics, Inc. - Common Stock

Intellia Therapeutics

Novavax

Praxis Precision Medicines, Inc. - Common Stock

Praxis Precision Medicine

Rocket Pharmaceuticals, Inc. - Common Stock

Rocket Pharmaceuticals

Arcus Biosciences

Syndax Pharmaceuticals, Inc. - Common Stock

Syndax Pharmaceuticals

ARS Pharmaceuticals

Spyre Therapeutics

Travere Therapeutics, Inc. - Common Stock

Travere Therapeutics

Vir Biotechnology

Viridian Therapeutics, Inc. - Common Stock

Comments

MiMedx Group

MiMedx Group (MDXG) 옵션

MiMedx Group (NASDAQ:MDXG) 주식, 옵션 체인

뉴스

파트너 / 기고자

벤징가 글로벌